dihexa fda approval status 2026 clinical trial dihexa human trials SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders 🧬 The FDA just made

FDA has only evaluated this drug for use under the chin

GHK-Cu does not inhibit ghrelin, does not stimulate GLP-1 receptors, and does not meaningfully alter insulin sensitivity

The use of research peptides outside of supervised research settings raises concerns about product quality, dosing accuracy, and lack of medical oversight

Research suggests that it works by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat accumulation), particularly in stubborn fat deposits such as the abdomen and thighs

Overall, these findings demonstrate that Cagrilintide exerts potent, RAMP-dependent effects on food intake, body weight, and neuronal activation